

Examiner Signature	<i>[Signature]</i>	Date Considered	4/13/04
-----------------------	--------------------	--------------------	---------

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

<b>Application Number</b>	10/029,750
<b>Filing Date</b>	December 21, 2001
<b>First Named Inventor</b>	LIN et al
<b>Group Art Unit</b>	626
<b>Examiner Name</b>	Robert Shira
<b>Attorney Docket Number</b>	ORT-1554

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
R.S.	5 /	AKAHOSHI, F., et al., "Synthesis and Pharmacological Activity of Triazolo [1,5-a] triazine Derivatives Inhibiting Eosinophilia," J. Med. Chem. 1998 41:2985-2993	
	6 /	DAVIS, S. T., et al., "Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors," Science 2001 291:134-137	
	7 /	DUNSTAN, A. R., et al., "Concise and regiospecific syntheses of tri-substituted 1,2,4-triazoles," Tetrahedron Letters 1998 39:7983-7986	
	8 /	GOULD, P. L., "Salt selection for basic drugs," International Journal of Pharma, 1986 33:201-217	
	9 /	HANCOCK, B. C., et al., "Characteristics and Significance of the Amorphous State in Pharmaceutical Systems," Journal of Pharma Sciences 1997 86(1):1-12	
	10 /	JENARDANAN, G. C., et al., "1-(N-ARYLTHIOCARBAMOYL) Amidino-3,5-Dimethyl Pyrazoles-Preparation and Use In Heterocycle Synthesis," Synthetic Communications 1997 27(19):3457-3462	
	11	McKEE, R. L., et al., "p-Substituted Phenyl Isothiocyanates and Some Related Thioureas," Journal of American Chem Soc 1946 68:2506-2507	
	12 /	NAITO, Y., et al., "Synthesis and Pharmacological Activity of Triazole Derivatives Inhibiting Eosinophilia," J. Med. Chem 1996 39:3019-3029	
	13 /	REITER, J., et al., "On Triazoles. VI [1] The acylation of 5-Amino-1,2,4-triazoles," J. Heterocyclic Chemistry 1987 24:127-142	
	14 /	ROSS, R., "The pathogenesis of atherosclerosis: a perspective for the 1990's," Nature 1993 362:801-808	
	15 /	WEBB, R. L., et al., "Diphenyl Cyancarbonimide and Dichlorodiphenoxymethane as Synthons for the Construction of Heterocyclic Systems of Medicinal Interest," J Heterocyclic Chemistry 1987 24:272-278.	
	16 /	WEI, G.L., et al., "Temporally and Spatially Coordinated Expression of Cell Cycle Regulatory Factors After Angioplasty," Circ. Res. 1997 80:418-426.	
	17 /	GenBank Accession U93306, Oct 27, 2000	
R.S.	18 /	Chem Abstract #214, Duvadie, R.K., et. al., "Novel ATP-Site Cyclin-Dependent Kinase"	
	19 /	Chem Abstract #215, Li, L., et. al., "Novel ATP-Site Cyclin-Dependent Kinase"	

Examiner Signature	<i>[Signature]</i>	Date Considered	4/13/14
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.